Skip to main content

Gabapentinoids

Gabapentinoids (gabapentin and pregabalin) are α2δ-1 voltage-gated calcium channel ligands originally developed as anticonvulsants and now widely used for neuropathic pain and neuromodulation. In urology they are deployed across off-label applications: chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS), interstitial cystitis / bladder pain syndrome (IC/BPS), chronic pelvic pain in women, neurogenic detrusor overactivity, MS-related spasticity with secondary bladder effects, ureteral stent-related symptoms, perioperative pain in urologic surgery, and (investigationally) premature ejaculation. None of these are FDA-approved.[1][2][3] Gabapentinoids also produce urologic adverse effects, including sexual dysfunction reported in selected cohorts and case-confirmed urinary incontinence.[1][2][3]

For the broader pelvic-pain framework, see Chronic Pelvic Pain. For other classes used in pelvic pain, see Neuropathic & Pelvic Pain pharmacology.

Mechanism — Why It Matters in Urology​

Gabapentinoids bind the α2δ-1 subunit of voltage-gated calcium channels in the CNS, reducing calcium-dependent release of excitatory neurotransmitters and decreasing neuronal excitability.[4] Several sites are urologically relevant:

  • Spinal dorsal horn and bladder α2δ-1. In female rats with LPS-induced chronic cystitis, dorsal-horn α2δ-1 expression increased and intrathecal gabapentinoids reduced pain behavior and voiding frequency.[5] In male mice with cyclophosphamide-induced cystitis, pregabalin reduced referred hyperalgesia and bladder inflammation.[6]
  • Locus coeruleus. In female rats with LPS-induced cystitis, noradrenergic nerve depletion reversed gabapentinoid analgesia but spared the effect on voiding frequency, implicating a descending noradrenergic pain pathway.[5]
  • Sacral spinal cord. In an uncontrolled study of 16 patients with neurogenic overactive bladder, urodynamic detrusor overactivity was lower after 31 days of gabapentin; the authors proposed altered bladder afferent input or sacral reflex-center excitability as mechanisms.[7]
  • Anti-inflammatory effect. Pregabalin reduces NF-κB pathway activation and pro-inflammatory cytokine production in cystitis models, suggesting a direct anti-inflammatory contribution beyond pure neuromodulation[6]

In rats with LPS-induced cystitis, gabapentinoids reduced pain behavior and voiding frequency; noradrenergic nerve depletion reversed analgesia but spared the voiding effect, implicating distinct pathways.[5]

Urologic Applications at a Glance​

ApplicationAgentBest evidencePractical position
CP/CPPSPregabalin, gabapentinRCT (pregabalin); retrospective comparison favoring gabapentin[8][9]May be considered as part of multimodal therapy [8][38]
IC/BPSGabapentin, pregabalinExtrapolated from neuropathic pain; no IC-specific RCTs[11]AUA 2022 Clinical Principle (Statement 13): pharmacologic pain agents after risk/benefit counseling, as for other chronic pain[11]
Chronic pelvic pain (women)Gabapentin, pregabalinGabapentin: GaPP2 found no significant worst or average pain benefit at weeks 13–16 after randomizing 306 women without obvious pelvic pathology at laparoscopy (worst-pain data for 246 and average-pain data for 244). ACOG 2020 recommends gabapentin and pregabalin for neuropathic CPP by extrapolation.[10][12]SOGC 445 recommends considering alternatives to gabapentin for CPP without gynecologic pathology; gabapentin may be an option for neuropathic pain (strong recommendation, moderate-certainty evidence).[47]
Localized provoked vulvodynia / pudendal nerve entrapmentGabapentin; gabapentinoidsExtended-release oral gabapentin RCT in localized provoked vulvodynia: no significant tampon-test benefit; pudendal nerve entrapment expert consensus[43][44]Pudendal entrapment: expert-consensus option for initial monotherapy
Neurogenic detrusor overactivityGabapentinPediatric RCT; adult open-label[13][7]Investigational / limited evidence
MS spasticity (with bladder effects)GabapentinSpasticity RCTs; consensus guidelines[14][23][24]NICE second-line after oral baclofen is unsuitable / inadequate; this is not a bladder indication
Ureteral stent symptoms (pain)PregabalinNetwork meta-analysis (best for pain domain in combination)[15]Adjunct to alpha-blocker / anticholinergic
Perioperative urologic painGabapentin, pregabalinAnesthesiology meta — no clinically significant benefit; URS RCT — increased pain[16][17]Not recommended routinely
Premature ejaculationPregabalinSingle RCT[18]Investigational; not among AUA/SMSNA 2020 first-line agents[46]

CP/CPPS — the most-studied urologic indication​

Pregabalin RCT (Pontari) and Cochrane​

In the NIH Chronic Prostatitis Collaborative Research Network trial (Pontari 2010), 324 men were randomized 2:1 to pregabalin (n = 218; titrated from 150 to 600 mg/day over 4 weeks) or placebo (n = 106) for 6 weeks:[42][8][20]

  • Primary endpoint (≥ 6-point NIH-CPSI improvement): 47.2% versus 35.8%, p = 0.07; failed[42]
  • Secondary outcomes: mean NIH-CPSI better with pregabalin (MD −2.4, p = 0.01); pain domain MD −1.0 (p = 0.04); urinary symptoms MD −0.70 (p = 0.01); QoL MD −0.70 (p = 0.02)[42]
  • GRA moderate / marked improvement: 31.2% versus 18.9% (p = 0.02)[42]

The Cochrane pregabalin review identified only this one RCT and found no difference in the responder rate (RR 1.32, 95% CI 0.99–1.76), with less pain on the NIH-CPSI pain domain and no serious adverse events.[20] The broader Cochrane review of CP/CPPS drugs rates most classes low or very low certainty.[19] The AUA guideline notes that the subscore gains may not be clinically meaningful.[38] EAU 2026 rates pregabalin as not effective for primary prostate pain syndrome (level 1b) and, for pelvic pain generally, cites a pregabalin dose range of 300–600 mg/day, notes that most patients gain no benefit and should stop the drug, and warns of dependence and misuse.[45] It cites the gabapentin trial in women with CPPPS and no obvious pathology as showing no benefit and more side effects.[45]

Gabapentin vs pregabalin (retrospective)​

A retrospective series of 119 men with UCPPS reported more improvement with gabapentin than pregabalin:[9]

  • ≥ 50% pain improvement: 47/62 (75.8%) on gabapentin alone versus 12/30 (40.0%) on pregabalin alone (p = 0.0012; reported NNT 2.9; nonrandomized comparison)[9]
  • 20 patients failed pregabalin and were switched to gabapentin
  • Need for adjunctive amitriptyline: 10/72 on gabapentin versus 24/54 on pregabalin (p = 0.0001; reported NNT 4)[9]

Clinical interpretation​

AUA’s 2025 male chronic pelvic pain guideline permits neuropathic-pain medicines including gabapentinoids for CP/CPPS . It reports no gabapentin trials in men with CP/CPPS.[38] If an individualized trial is chosen, document the pain mechanism, functional goal, adverse effects and reassessment/stop plan.

IC/BPS​

There are no IC/BPS-specific RCTs. Use rests on extrapolation from neuropathic-pain evidence and the central-sensitization model.[11]

  • The 2022 AUA IC/BPS Guideline addresses pharmacological pain management as a Clinical Principle: clinicians may prescribe pharmacologic pain agents after counseling on risks and benefits, using the same principles as for other chronic pain, within a multimodal plan (Statement 13). Gabapentinoids fit under this umbrella but are not specifically named[11]
  • Preclinical evidence is strong: gabapentinoids reduce bladder pain behaviors and voiding frequency in LPS-induced chronic cystitis; α2δ-1 is upregulated in spinal dorsal horn and locus coeruleus in cystitis models; mirogabalin shows longer-lasting analgesic effects in models[5][6]
  • Practical use: off-label as part of multimodal analgesia, particularly when neuropathic features (allodynia, hyperalgesia, multiple overlapping pain conditions) are prominent

Chronic Pelvic Pain in Women​

ACOG 2020 vs the GaPP2 trial​

ACOG (2020) recommends gabapentin and pregabalin for neuropathic chronic pelvic pain based on extrapolation from other neuropathic pain syndromes; GaPP2 was published afterward.[10][21]

The GaPP2 multicentre RCT (n = 306) of gabapentin titrated to 2,700 mg/day (900 mg TID) over 16 weeks for women with chronic pelvic pain and no obvious pelvic pathology was negative:[12]

  • No significant difference in either worst or average pain at weeks 13–16
  • Serious adverse events occurred in 7% versus 2%; dizziness, drowsiness and visual disturbance were more common with gabapentin[12]
  • The trial was adequately powered, gabapentin did not lower pain, and the authors advised considering alternatives to off-label gabapentin for chronic pelvic pain without obvious pelvic pathology (participants were aged 18–50 with negative laparoscopy)

Practical interpretation​

The high-quality RCT evidence is against routine gabapentin for undifferentiated CPP. SOGC Guideline No. 445 (2024) recommends considering alternatives to gabapentin for CPP without gynecologic pathology and states that gabapentin may be an option for neuropathic pain .[47] GaPP2 did not validate a responder subgroup based on allodynia or a lidocaine challenge.

Vulvodynia and pudendal neuralgia​

  • Vulvodynia: in a crossover RCT (n = 89) of extended-release gabapentin 1,200–3,000 mg/day, tampon-test pain did not differ from placebo (4.0 versus 4.3; P = .07), nor did intercourse or daily pain. The authors concluded the data do not support gabapentin alone for vulvodynia.[43] If used, treat it as an adjunct within a multimodal plan.
  • Pudendal nerve entrapment: a formalised French expert consensus (2022) prefers initial monotherapy with tricyclics or gabapentinoids and found no benefit from opioids.[44]

Neurogenic Detrusor Overactivity​

Pediatric RCT (spina bifida, n = 44)​

Gabapentin versus oxybutynin versus the combination:[13]

  • All three groups improved symptoms and urodynamics
  • Best response in the combination group
  • Gabapentin better tolerated than oxybutynin (fewer anticholinergic effects)
  • Conclusion: gabapentin is "a good alternative to oxybutynin … both as monotherapy and as add-on"

Adult open-label (n = 16)​

Gabapentin (31 days) in neurogenic OAB significantly modified urodynamic indices (especially detrusor overactivity), reduced irritative symptom scores and frequency, with no patient discontinuing for AEs.[7]

Preclinical​

In a rat model of neurogenic detrusor overactivity after spinalization, both pregabalin and lamotrigine improved baseline pressure, detrusor pressure at maximum capacity, capacity, and the frequency of overactivity.[22]

Clinical role​

The AUA/SUFU NLUTD guideline conditionally recommends antimuscarinics or beta-3 adrenergic receptor agonists, alone or together, to improve bladder storage parameters .[48]

MS Spasticity with Secondary Bladder Effects​

Older reviews listed gabapentin among antispasticity options. Current NICE NG220 places it second-line after oral baclofen is not tolerated or insufficient; counsel about dependence and respiratory or CNS adverse effects.[39][14][23][24][25]

  • A placebo-controlled crossover RCT enrolled 22 adults with chronic progressive MS; 21 completed after one withdrew on the first gabapentin day because of headache. Gabapentin 900 mg TID reduced Modified Ashworth Scale scores, spasm severity, interference with function, and painful spasms without detected worsening of concentration or fatigue.[14]
  • An earlier crossover study (n = 15) at 400 mg TID also improved Ashworth, Visual Faces, and Kurtzke scores[25]

Urologic relevance: the same spinal-cord mechanisms that drive limb spasticity also contribute to detrusor overactivity and DSD in MS.

Ureteral Stent–Related Symptoms​

A Bayesian network meta-analysis (26 RCTs) of pharmacologic management of stent symptoms found that for the pain domain, combined anticholinergic plus pregabalin ranked highly.[15]

  • For urinary symptoms, sexual performance, general health, and work performance, the best classes were combined α-blocker plus anticholinergic and PDE5 inhibitors
  • Rankings of individual regimens differed from class rankings, and much of the comparison was indirect

Perioperative Use in Urologic Surgery​

Gabapentinoids have been incorporated into many ERAS protocols, but recent evidence has tempered enthusiasm.

Anesthesiology meta-analysis (281 RCTs, N = 24,682)[16]​

  • Reduced postoperative pain at 6, 12, 24, and 48 h (rounded mean differences −10, −9, −7, and −3 points on a 100-point scale); authors judged the effects clinically unimportant[16]
  • No effect on subacute or chronic pain prevention
  • Lower PONV but more dizziness and visual disturbance
  • "Results do not support the routine use of pregabalin or gabapentin" for postoperative pain in adults

Ureteroscopy-specific RCT (n = 118)[17]​

Single-dose perioperative pregabalin 300 mg versus placebo for URS: [17]

  • Postoperative pain scores higher with pregabalin (3.7 versus 2.0; p = 0.004)
  • No difference in cognition or AEs
  • "Urologists should not routinely use this adjunctive medication in ureteroscopy"

Older adults​

Park’s observational cohort associated perioperative gabapentin with delirium, new antipsychotic use and pneumonia. Beers advises avoiding gabapentinoid–opioid combinations in most circumstances, reducing doses with impaired renal function and considering falls or CNS polypharmacy.[40][26]

Bottom line​

Routine perioperative use in urologic surgery is not supported.[16][27][28][37]

Premature Ejaculation (Investigational)​

A single double-blind, placebo-controlled RCT (120 men enrolled; 116 completed the 2-week trial) of on-demand pregabalin:[18]

  • 150 mg pregabalin 1–2 h before intercourse improved IELT versus placebo [18]
  • 75 mg showed no effect [18]
  • Small, short-term (2 weeks)
  • Conclusion: "promising drug for additional evaluation"

AUA/SMSNA 2020 recommends daily SSRIs, on-demand clomipramine or dapoxetine where available, and topical penile anesthetics as first-line PE pharmacotherapy .[46] Pregabalin is not included in this list.[46] The proposed mechanism is more likely a side-effect (delayed ejaculation) than a therapeutic effect.[18][29]

Idiopathic OAB (Limited Evidence)​

A multicenter randomized double-blind crossover (n = 519 treatment periods) in women with idiopathic OAB:[30]

  • Pregabalin 150 mg BID alone had a greater baseline-adjusted four-week increase in mean voided volume per micturition than tolterodine ER alone (27.4 versus 15.5 mL, p = 0.005) or placebo (11.9 mL, p = 0.0006)[30]
  • Pregabalin 150 mg BID plus tolterodine ER 4 mg daily had the largest baseline-adjusted four-week increase in mean voided volume per micturition (39.5 versus 15.5 mL for tolterodine ER 4 mg daily)[30]

A separate retrospective study found no adjusted anticholinergic response advantage with preexisting gabapentin.[31]

Urologic Adverse Effects — Frequently Missed​

The gabapentin and pregabalin labels list sexual adverse events; the pregabalin label also lists urinary adverse events. Review gabapentinoid use when new lower urinary tract or sexual symptoms arise.[2][3]

Pregabalin (FDA label — urogenital system)[3]​

  • Frequent: anorgasmia, impotence, urinary frequency, urinary incontinence
  • Infrequent: abnormal ejaculation, dysuria, hematuria, kidney calculus, oliguria, urinary retention
  • Rare: acute kidney failure, epididymitis

Gabapentin (FDA label — postmarketing)[2][32]​

Breast enlargement, libido changes, ejaculation disorders, anorgasmia.

Sexual dysfunction can occur​

A case series of 75 pregabalin-treated patients reported sexual dysfunction in 41.3%:[33]

  • Among the 31 of 75 selected patients who reported sexual dysfunction, the authors described erectile dysfunction, anorgasmia, and low libido.
  • In this case series, onset was within weeks and was reported even at 50–100 mg/day without a dose relationship[33]
  • Resolves within weeks of discontinuation

Gabapentin-induced sexual dysfunction is reported at doses as low as 300 mg/day, including total sexual dysfunction (loss of libido, anejaculation, anorgasmia, impotence).[34]

Urinary incontinence​

A case report documents gabapentin-associated urinary incontinence verified by rechallenge: onset within 1 day of initiation, resolution within 2 days of discontinuation.[35] A pharmacovigilance analysis of FAERS identified neuropsychiatric drugs (including gabapentinoids) among disproportional reporting signals for urinary incontinence. Among 6,059 urinary-incontinence reports with complete onset dates across the analyzed drugs, 57.12% occurred within 30 days of medication initiation.[36]

Pragmatic point: ask about gabapentinoid use in any patient presenting with new-onset incontinence or sexual dysfunction.

Practical prescribing and safety​

There is no validated universal pelvic-pain dose. Select an agent for a defined indication, titrate gradually and stop if benefit does not justify harms. Immediate-release gabapentin and pregabalin have different dose ranges and renal tables; do not transfer a high neuropathic-pain target directly into a frail, renally impaired or pediatric patient.[2][3]

Gabapentin (Neurontin label)Pregabalin (Lyrica label)
Labeled pain indicationsPostherpetic neuralgia onlyDiabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, spinal cord injury neuropathic pain
Label titration (PHN)300 mg day 1, 600 mg/day day 2, 900 mg/day day 3; up to 1,800 mg/day; no added benefit shown above 1,800 mg/day [2]Start 150 mg/day; 300 mg/day within 1 week; up to 600 mg/day only after 2–4 weeks at 300 mg/day if pain relief is insufficient and 300 mg/day is tolerated [3]
Renal adjustment (CrCl, mL/min)≥60: 900–3,600 mg/day; >30 to 59: 400–1,400 mg/day; >15 to 29: 200–700 mg/day once daily; CrCl 15: 100–300 mg/day once daily; <15: reduce the CrCl-15 daily dose in proportion to clearance [2]≥60: 150–600 mg/day; 30–60: 75–300 mg/day; 15–30: 25–150 mg/day; <15: 25–75 mg/day once daily; supplemental dose after hemodialysis [3]
SchedulingNot federally scheduledSchedule V

Pelvic-pain trials used gabapentin up to 2,700 mg/day in GaPP2 and pregabalin up to 600 mg/day in the CP/CPPS trial.[12][42] The AUA male chronic pelvic pain guideline discusses starting gabapentin at 100–300 mg nightly in younger men to limit daytime somnolence.[38] Table values are label figures for immediate-release products; confirm against the current label.

  • Renal clearance: check CrCl and use the product-specific adjustment table before starting and after renal-function changes. Dialysis requires additional product-specific instructions.
  • Respiratory depression: FDA warns of serious or fatal breathing problems with opioids or other CNS depressants or underlying respiratory impairment (Warnings and Precautions in both labels; December 2019 FDA safety communication). This is not a boxed warning; start at a low dose and monitor when co-prescribing.[2][3][41]
  • Other safety checks: sedation, falls, edema/weight gain, mood or suicidal symptoms (antiepileptic-class warning), angioedema/anaphylaxis (stop immediately), and DRESS/multiorgan hypersensitivity (gabapentin label; stop if no alternative cause). Review concurrent sedatives and counsel about driving.[2][3]
  • Pregnancy and lactation: before off-label pregabalin for CPP, ask about pregnancy and breastfeeding plans. The Lyrica label describes a possible small increase in overall major birth defects without a consistent pattern and does not recommend breastfeeding during treatment; review the indication and alternatives with the patient. After prolonged pregabalin and opioid exposure near delivery, arrange neonatal observation for withdrawal signs.[3]
  • Dependence/withdrawal: pregabalin is US Schedule V; misuse can occur with either drug. Taper rather than stopping abruptly (withdrawal symptoms, seizures and suicidal ideation are described after abrupt discontinuation); label minimum taper is one week, and a slower individualized taper may be needed.
  • Older adults: review renal dose, falls risk, opioid combination and cumulative CNS medicines.[2][3][40]

Clinical Positioning​

  • Every urologic use of gabapentinoids is off-label, and most rest on small studies, extrapolation, or preclinical models[1]
  • CP/CPPS: selected neuropathic-pain treatment may be tried with reassessment, but the pregabalin RCT missed its primary endpoint
  • Chronic pelvic pain in women. The GaPP2 RCT was negative; reserve for clearly neuropathic phenotype, not undifferentiated CPP[12]
  • Neurogenic OAB. Small-study evidence is insufficient to replace established storage-pressure management[13]
  • MS. NICE considers gabapentin second-line for MS spasticity after inadequate or intolerable oral baclofen; a secondary bladder benefit is unproven.[14][23][39]
  • Perioperative urologic surgery. Not recommended routinely; the URS RCT actually found higher pain with pregabalin[16][17]
  • Sexual dysfunction and incontinence are frequently missed AEs; ask about gabapentinoid use in new-onset cases[33][35]
  • The Goodman & Brett JAMA Internal Medicine overview is direct: "the evidence to support off-label gabapentinoid use for most painful clinical conditions is limited"; discontinue when patients perceive little or no benefit[1]

See Also​

References​

1. Goodman CW, Brett AS. "A clinical overview of off-label use of gabapentinoid drugs." JAMA Intern Med. 2019;179(5):695–701. doi:10.1001/jamainternmed.2019.0086

2. Viatris. NEURONTIN (gabapentin): prescribing information. DailyMed. Accessed September 24, 2026.

3. Viatris. LYRICA (pregabalin): prescribing information. DailyMed. Accessed September 12, 2026.

4. Finnerup NB. "Nonnarcotic methods of pain management." N Engl J Med. 2019;380(25):2440–2448. doi:10.1056/NEJMra1807061

5. Yoshizumi M, Kitano Y, Watanabe C, Sakurada S, Mizoguchi H. "Characterization of actions of the novel gabapentinoid drug mirogabalin on painful bladder hypersensitivity in rats with lipopolysaccharide-induced chronic cystitis." Life Sci. 2025:123942. doi:10.1016/j.lfs.2025.123942

6. Boudieu L, Mountadem S, Lashermes A, et al. "Blocking α2δ-1 subunit reduces bladder hypersensitivity and inflammation in a cystitis mouse model by decreasing NF-κB pathway activation." Front Pharmacol. 2019;10:133. doi:10.3389/fphar.2019.00133

7. Carbone A, Palleschi G, et al. "Gabapentin treatment of neurogenic overactive bladder." Clin Neuropharmacol. 2006;29(4):206–214. doi:10.1097/01.WNF.0000228174.08885.AB

8. Borgert BJ, Wallen EM, Pham MN. "Prostatitis." JAMA. 2025;334(11):1003–1013. doi:10.1001/jama.2025.11499

9. Agarwal MM, Elsi Sy M. "Gabapentenoids in pain management in urological chronic pelvic pain syndrome: gabapentin or pregabalin?" Neurourol Urodyn. 2017;36(8):2028–2033. doi:10.1002/nau.23225

10. American College of Obstetricians and Gynecologists. "Chronic pelvic pain: ACOG Practice Bulletin, Number 218." Obstet Gynecol. 2020;135(3):e98–e109. doi:10.1097/AOG.0000000000003716

11. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

12. Horne AW, Vincent K, Hewitt CA, et al. "Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial." Lancet. 2020;396(10255):909–917. doi:10.1016/S0140-6736(20)31693-7

13. Dash V, Bawa M, Mahajan JK, et al. "Role of gabapentin and anticholinergics in management of neurogenic bladder after repair of spina bifida — a randomized controlled study." J Pediatr Surg. 2016;51(12):2025–2029. doi:10.1016/j.jpedsurg.2016.09.030

14. Cutter NC, Scott DD, Johnson JC, Whiteneck G. "Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial." Arch Phys Med Rehabil. 2000;81(2):164–169. doi:10.1016/s0003-9993(00)90135-7

15. Hinojosa-Gonzalez DE, Segall MR, Eisner BH. "Pharmacological management of ureteral stent-related symptoms: a systematic review, Bayesian network meta-analysis, and meta-regression." J Urol. 2023;210(5):739–749. doi:10.1097/JU.0000000000003616

16. Verret M, Lauzier F, Zarychanski R, et al. "Perioperative use of gabapentinoids for the management of postoperative acute pain: a systematic review and meta-analysis." Anesthesiology. 2020;133(2):265–279. doi:10.1097/ALN.0000000000003428

17. Rosen GH, Hargis PA, Kahveci A, et al. "Randomized controlled trial of single-dose perioperative pregabalin in ureteroscopy." J Urol. 2023;210(3):517–528. doi:10.1097/JU.0000000000003572

18. El Najjar MR, El Hariri M, Ramadan A, Hefny Hashem AA. "A double blind, placebo controlled, randomized trial to evaluate the efficacy and tolerability of on-demand oral pregabalin (150 mg and 75 mg) in treatment of premature ejaculation." J Sex Med. 2020;17(3):442–446. doi:10.1016/j.jsxm.2019.12.014

19. Franco JV, Turk T, Jung JH, et al. "Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome." Cochrane Database Syst Rev. 2019;10:CD012552. doi:10.1002/14651858.CD012552.pub2

20. Aboumarzouk OM, Nelson RL. "Pregabalin for chronic prostatitis." Cochrane Database Syst Rev. 2012;(8):CD009063. doi:10.1002/14651858.CD009063.pub2

21. Arnold MJ, Osgood AT, Aust A. "Chronic pelvic pain in women: ACOG updates recommendations." Am Fam Physician. 2021;103(3):186–188. PMID 33507045

22. Loutochin O, Al Afraa T, Campeau L, et al. "Effect of the anticonvulsant medications pregabalin and lamotrigine on urodynamic parameters in an animal model of neurogenic detrusor overactivity." Neurourol Urodyn. 2012;31(7):1197–1202. doi:10.1002/nau.21214

23. Gold R, Oreja-Guevara C. "Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines." Expert Rev Neurother. 2013;13(12 Suppl):55–59. doi:10.1586/14737175.2013.865880

24. Haas J. "Pathophysiology, assessment and management of multiple sclerosis spasticity: an update." Expert Rev Neurother. 2011;11(4 Suppl):3–8. doi:10.1586/ern.11.25

25. Mueller ME, Gruenthal M, Olson WL, Olson WH. "Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis." Arch Phys Med Rehabil. 1997;78(5):521–524. doi:10.1016/s0003-9993(97)90168-4

26. Park CM, Inouye SK, Marcantonio ER, et al. "Perioperative gabapentin use and in-hospital adverse clinical events among older adults after major surgery." JAMA Intern Med. 2022;182(11):1117–1127. doi:10.1001/jamainternmed.2022.3680

27. Patel AS, Abrecht CR, Urman RD. "Gabapentinoid use in perioperative care and current controversies." Curr Pain Headache Rep. 2022;26(2):139–144. doi:10.1007/s11916-022-01012-2

28. Kumar AH, Habib AS. "The role of gabapentinoids in acute and chronic pain after surgery." Curr Opin Anaesthesiol. 2019;32(5):629–634. doi:10.1097/ACO.0000000000000767

29. Raisi F, Soleimani R, Ahmadzadeh A, et al. "Efficacy and safety of pharmacological treatments in patients with premature ejaculation: an umbrella review of meta-analyses of randomized controlled trials." J Sex Med. 2025;22(6):1014–1023. doi:10.1093/jsxmed/qdaf094

30. Marencak J, Cossons NH, Darekar A, Mills IW. "Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder." Neurourol Urodyn. 2011;30(1):75–82. doi:10.1002/nau.20928

31. Roberts K, Dao A, Alfahmy A, Mitchell D, Sheyn D. "Does gabapentin impact response to anticholinergics for overactive bladder?" Int Urogynecol J. 2022;33(9):2501–2506. doi:10.1007/s00192-022-05231-4

32. DailyMed. Gabapentin: prescribing information, adverse reactions and postmarketing experience. Label. Accessed September 12, 2026.

33. Hamed SA. "Sexual dysfunctions induced by pregabalin." Clin Neuropharmacol. 2018;41(4):116–122. doi:10.1097/WNF.0000000000000286

34. Kaufman KR, Struck PJ. "Gabapentin-induced sexual dysfunction." Epilepsy Behav. 2011;21(3):324–326. doi:10.1016/j.yebeh.2011.04.058

35. Rissardo JP, Caprara ALF. "Gabapentin-associated urinary incontinence: a case verified by rechallenge." Clin Neuropharmacol. 2019;42(3):91–93. doi:10.1097/WNF.0000000000000334

36. Li C, Wu C, Cai S, Wang L. "Pharmacovigilance evidence of drug induced urinary incontinence in the FDA Adverse Event Reporting System." Sci Rep. 2025;15(1):38278. doi:10.1038/s41598-025-23379-z

37. Wick EC, Grant MC, Wu CL. "Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review." JAMA Surg. 2017;152(7):691–697. doi:10.1001/jamasurg.2017.0898

38. Lai HH, Pontari MA, Argoff CE, et al. Male Chronic Pelvic Pain: AUA Guideline: Part II Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. J Urol. 2025;214(2):127-137. doi:10.1097/JU.0000000000004565 Full 2025 guideline

39. NICE. Multiple sclerosis in adults: management (NG220). Spasticity recommendations. Current guidance.

40. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71:2052–2081. doi:10.1111/jgs.18372.

41. US FDA. Gabapentin and pregabalin: serious breathing problems. December 2019. Drug safety communication.

42. Pontari MA, Krieger JN, Litwin MS, et al. "Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial." Arch Intern Med. 2010;170(17):1586–1593. doi:10.1001/archinternmed.2010.319

43. Brown CS, Bachmann GA, Wan J, Foster DC. "Gabapentin for the treatment of vulvodynia: a randomized controlled trial." Obstet Gynecol. 2018;131(6):1000–1007. doi:10.1097/AOG.0000000000002617

44. Levesque A, Bautrant E, Quistrebert V, et al. "Recommendations on the management of pudendal nerve entrapment syndrome: a formalised expert consensus." Eur J Pain. 2022;26(1):7–17. doi:10.1002/ejp.1861

45. Engeler D, Baranowski AP, Berghmans B, et al. EAU Guidelines on Chronic Pelvic Pain. European Association of Urology; limited update March 2026. Guideline

46. Shindel AW, Althof SE, Carrier S, et al. Disorders of Ejaculation: An AUA/SMSNA Guideline. J Urol. 2022;207(3):504-512. doi:10.1097/JU.0000000000002392 (2020 guideline).

47. Allaire C, Yong PJ, Bajzak K, et al. "Guideline No. 445: Management of Chronic Pelvic Pain." J Obstet Gynaecol Can. 2024;46(1):102283. doi:10.1016/j.jogc.2023.102283

48. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-up." J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239